<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39459552</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness and Safety of Remdesivir Use in COVID-19 Patients with Neutropenia: A Retrospective Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1252</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life14101252</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic poses severe risks for immunocompromised patients, especially those with neutropenia due to chemotherapy. This study evaluates the safety and effectiveness of remdesivir use in COVID-19 patients with neutropenia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study used the Chang Gung Research Database (CGRD) and extracted data from 98,763 patients with COVID-19 diagnosed between April 2021 and September 2022. The patients were divided into groups based on their remdesivir use and the presence of neutropenia. The adverse effects of remdesivir and their outcomes were analyzed after propensity score matching.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We compared common adverse effects of remdesivir in neutropenic patients before and after a 5-day regimen. A slight decrease in heart rate was observed but lacked clinical significance. There were no significant differences observed in hemoglobin, liver function tests, and blood glucose levels. After propensity score matching of COVID-19 patients with neutropenia according to gender, age, dexamethasone use, oxygen use, MASCC score, and WHO ordinal scale, no significant differences were found in length of stay, intubation rate, or ICU admission rate between the matched patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study found remdesivir to be safe for COVID-19 patients with neutropenia, with no common adverse reactions observed. However, its effectiveness for these patients remains uncertain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Peng-Huei</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ming-Wei</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, En Chu Kong Hospital, New Taipei City 237, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yan-Bo</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Chip-Jin</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0003-0363-2938</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shou-Yen</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-3039-9644</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Management, College of Management, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MASCC</Keyword><Keyword MajorTopicYN="N">WHO ordinal scale</Keyword><Keyword MajorTopicYN="N">neutropenia</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459552</ArticleId><ArticleId IdType="pmc">PMC11508965</ArticleId><ArticleId IdType="doi">10.3390/life14101252</ArticleId><ArticleId IdType="pii">life14101252</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stokes E.K., Zambrano L.D., Anderson K.N., Marder E.P., Raz K.M., El Burai Felix S., Tie Y., Fullerton K.E. Coronavirus Disease 2019 Case Surveillance—United States, January 22–May 30, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:759–765. doi: 10.15585/mmwr.mm6924e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6924e2</ArticleId><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Salvo E., Di Gioacchino M., Tonacci A., Casciaro M., Gangemi S. Alarmins, COVID-19 and comorbidities. Ann. Med. 2021;53:777–785. doi: 10.1080/07853890.2021.1921252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2021.1921252</ArticleId><ArticleId IdType="pmc">PMC8168739</ArticleId><ArticleId IdType="pubmed">34042528</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivas P., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A., et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. Ann. Oncol. 2021;32:787–800. doi: 10.1016/j.annonc.2021.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.02.024</ArticleId><ArticleId IdType="pmc">PMC7972830</ArticleId><ArticleId IdType="pubmed">33746047</ArticleId></ArticleIdList></Reference><Reference><Citation>Infectious Diseases Society of America  IDSA Guidelines on the Treatment and Management of Patients with COVID-19.  [(accessed on 6 August 2024)].  Available online:  https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</Citation></Reference><Reference><Citation>National Institutes of Health  COVID-19 Treatment Guidelines.  [(accessed on 6 August 2024)]; Available online:  https://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf.</Citation></Reference><Reference><Citation>Agarwal A., Hunt B., Stegemann M., Rochwerg B., Lamontagne F., Siemieniuk R.A., Agoritsas T., Askie L., Lytvyn L., Leo Y.S., et al. A living WHO guideline on drugs for COVID-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19—Final Report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q., Alejandria M.M., Hernández García C., Kieny M.P., Malekzadeh R., et al. Repurposed Antiviral Drugs for COVID-19—Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497–511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S., Hayakawa K., Uemura Y., Shinozaki T., Matsunaga N., Terada M., Suzuki S., Asai Y., Kitajima K., Saito S., et al. Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan. Int. J. Infect. Dis. 2022;118:119–125. doi: 10.1016/j.ijid.2022.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.02.039</ArticleId><ArticleId IdType="pmc">PMC8857764</ArticleId><ArticleId IdType="pubmed">35192953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanafusa M., Nawa N., Goto Y., Kawahara T., Miyamae S., Ueki Y., Nosaka N., Wakabayashi K., Tohda S., Tateishi U., et al. Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study. J. Med. Virol. 2023;95:e28168. doi: 10.1002/jmv.28168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28168</ArticleId><ArticleId IdType="pmc">PMC9538844</ArticleId><ArticleId IdType="pubmed">36148941</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska K., Zarębska-Michaluk D., Brzdęk M., Rzymski P., Rogalska M., Moniuszko-Malinowska A., Kozielewicz D., Hawro M., Rorat M., Sikorska K., et al. Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. J. Clin. Med. 2023;12:2371. doi: 10.3390/jcm12062371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12062371</ArticleId><ArticleId IdType="pmc">PMC10051185</ArticleId><ArticleId IdType="pubmed">36983370</ArticleId></ArticleIdList></Reference><Reference><Citation>Breskin A., Wiener C., Adimora A.A., Brown R.S., Jr., Landis C., Reddy K.R., Verna E.C., Crawford J.M., Mospan A., Fried M.W., et al. Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. Epidemiology. 2023;34:365–375. doi: 10.1097/EDE.0000000000001598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001598</ArticleId><ArticleId IdType="pubmed">36719738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Devgun J.M., Zhang R., Brent J., Wax P., Burkhart K., Meyn A., Campleman S., Abston S., Aldy K. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. JAMA Netw. Open. 2023;6:e2255815. doi: 10.1001/jamanetworkopen.2022.55815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.55815</ArticleId><ArticleId IdType="pmc">PMC9929701</ArticleId><ArticleId IdType="pubmed">36787141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadori G., Cameron S. Effects of systemic chemotherapy on the liver. Ann. Hepatol. 2010;9:133–143. doi: 10.1016/S1665-2681(19)31651-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1665-2681(19)31651-5</ArticleId><ArticleId IdType="pubmed">20526005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.S., Lin M.H., Lee C.P., Yang Y.H., Chen W.C., Chang G.H., Tsai Y.T., Chen P.C., Tsai Y.H. Chang Gung Research Database: A multi-institutional database consisting of original medical records. Biomed. J. 2017;40:263–269. doi: 10.1016/j.bj.2017.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC6138604</ArticleId><ArticleId IdType="pubmed">29179881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio-Rivas M., Mora-Luján J.M., Formiga F., Arévalo-Cañas C., Lebrón Ramos J.M., Villalba García M.V., Fonseca Aizpuru E.M., Díez-Manglano J., Arnalich Fernández F., Romero Cabrera J.L., et al. WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. J. Gen. Intern. Med. 2022;37:1980–1987. doi: 10.1007/s11606-022-07511-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07511-7</ArticleId><ArticleId IdType="pmc">PMC8992782</ArticleId><ArticleId IdType="pubmed">35396659</ArticleId></ArticleIdList></Reference><Reference><Citation>Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 2011;52:e56–e93. doi: 10.1093/cid/cir073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cir073</ArticleId><ArticleId IdType="pubmed">21258094</ArticleId></ArticleIdList></Reference><Reference><Citation>Klastersky J., Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support. Care Cancer. 2013;21:1487–1495. doi: 10.1007/s00520-013-1758-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-013-1758-y</ArticleId><ArticleId IdType="pubmed">23443617</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Xiao W., Shi L., Wang Y., Yang H. Is Cancer an Independent Risk Factor for Fatal Outcomes of Coronavirus Disease 2019 Patients? Arch. Med. Res. 2021;52:755–760. doi: 10.1016/j.arcmed.2021.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.05.003</ArticleId><ArticleId IdType="pmc">PMC8142843</ArticleId><ArticleId IdType="pubmed">34074544</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi Y.M., Sehrawat A., Panda P.K., Nath U.K. Febrile neutropenia due to COVID-19 in an immunocompetent patient. BMJ Case Rep. 2021;14:e242683. doi: 10.1136/bcr-2021-242683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-242683</ArticleId><ArticleId IdType="pmc">PMC8074537</ArticleId><ArticleId IdType="pubmed">33893137</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Pereira P., Iturrate I., de La Cámara R., Cardeñoso L., Alegre A., Aguado B. Can COVID-19 cause severe neutropenia? Clin. Case Rep. 2020;8:3349–3351. doi: 10.1002/ccr3.3369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.3369</ArticleId><ArticleId IdType="pmc">PMC7752313</ArticleId><ArticleId IdType="pubmed">33363932</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundeis F., Ansems K., Dahms K., Thieme V., Metzendorf M.I., Skoetz N., Benstoem C., Mikolajewska A., Griesel M., Fichtner F., et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst. Rev. 2023;1:Cd014962. doi: 10.1002/14651858.CD014962.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD014962.pub2</ArticleId><ArticleId IdType="pmc">PMC9875553</ArticleId><ArticleId IdType="pubmed">36695483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffari E., Chandak A., Gottlieb R.L., Chima-Melton C., Read S.H., Jiang H., Chiang M., Lee E., Gupta R., Berry M., et al. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. Clin. Infect. Dis. 2023;77:1626–1634. doi: 10.1093/cid/ciad460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad460</ArticleId><ArticleId IdType="pmc">PMC10724457</ArticleId><ArticleId IdType="pubmed">37556727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossey J., Cote M.C.B. Evaluation and management of febrile neutropenia in patients with cancer. Jaapa. 2024;37:16–20. doi: 10.1097/01.JAA.0000000000000054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JAA.0000000000000054</ArticleId><ArticleId IdType="pubmed">38980295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoix J.P., Schmit J.L., Douadi Y. Bacterial lung sepsis in patients with febrile neutropenia. Curr. Opin. Pulm. Med. 2012;18:175–180. doi: 10.1097/MCP.0b013e328351f8e8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCP.0b013e328351f8e8</ArticleId><ArticleId IdType="pubmed">22343426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A.W., Morjaria S., Kaltsas A., Hohl T.M., Parameswaran R., Patel D., Zhou W., Predmore J., Perez-Johnston R., Jee J., et al. The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With Coronavirus Disease 2019 (COVID-19) Infection. Clin. Infect. Dis. 2022;74:567–574. doi: 10.1093/cid/ciab534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab534</ArticleId><ArticleId IdType="pmc">PMC8406899</ArticleId><ArticleId IdType="pubmed">34111237</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M., Daßler-Plenker J., Guerci P., Huynh C., Knight J.S., et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;217:e20200652. doi: 10.1084/jem.20200652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Taiwan Centers for Disease Control  The Clinical Management Guidelines for Novel Coronavirus (SARS-CoV-2) Infection.  [(accessed on 6 August 2024)]; Available online:  https://www.cdc.gov.tw/Category/Page/xCSwc5oznwcqunujPc-qmQ.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>